Zoll Medical--LifeVest:
|
|
- Emmeline Watkins
- 5 years ago
- Views:
Transcription
1 Zoll Medical--LifeVest: Territory Manager: Sunny Brown Cell: (818)
2 Objectives Why the LifeVest device exist Review indications for Wearable Cardioverter Defibrillator (WCD) use Give a brief description of the LifeVest Technology
3 Why the LifeVest Exist
4 Survival Statistics Survival with AED 4-10% (1) In-hospital survival to discharge 13-24% (2) Casino 74% (3) WCD 92-98% (1) Nichol et al. Circ, April 21, (2) Peberdy, et al, RESUSCITATION 58 (2003) (3) Valenzuela et al., NEJM. Oct 26, , 2000.
5 Cardiovascular Death 1 out of every 3 deaths in US (1) 2,150 Americans die each day from CVD (1 every 40 seconds) (1) CVD claims more lives each year than all forms of cancer, combined (1) (1)AHA Heart Disease and Stroke Statistics-2015 Update
6 CVD and SCD SCA and it s consequence; SCD, account for approximately 50% of all cardiovascular deaths (1) At least 25% of these events are the patient s first symptomatic event (1,2) (1)Myerburg RJ, Juntilla MJ. Sudden cardiac death caused by coronary heart disease. Circulation 2012;125: Goldberger JJ, Buxton AE, Cain M, et al. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011;123: (2) Fishman GI, Chugh SS, DiMarco JP, et al. Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and HRS Workshop. Circulation. 2010;122: Myerburg RJ. Sudden cardiac death: exploring the limits of our knowledge. J Cardiovascular Electrophysiol. 2001;12:
7 SCD & Out of Hospital Cardiac Arrest In 2017 update of cardiovascular statistics from AHA, estimated Out of hospital cardiac arrest at 356,500 annually Overall survival of out of hospital cardiac arrest is 10% Among the subgroup of 70% out of hospital cardiac arrests that occur in the home, survival rate is 6% In 2011, of the 19,300 bystander-witnessed out of hospital cardiac arrests, 31.4% survived.
8 Out of Hospital Cardiac Arrest Factors determining survival after out of hospital cardiac arrest Time between collapse and start of resuscitation Time to defibrillation Availability of AED s in public
9 In-Hospital Cardiac Arrest 2017 AHA Update: 209,000 in-hospital cardiac arrests occur annually. (1) 2017: Rate of survival to D/C after in-hospital cardiac arrest is 24% (2) 2013: NRCPR data (17,991 cardiac arrests/250 hospitals) 17% survival rate in-hospital --18% Daytime --13% Night (1) Merchant RM, Yang L, Becker LB et al. Incidence of treated cardiac arrest in hospitalized patients in the United States. Crit Care Med. 2011;39: (2) Daya MR, Schmicker R, MaySH, et al. Current burden of cardiac arrest in the United States: report from the Resuscitation Outcomes Consortium. Paper commissioned by the Committee on the Treatment of Cardiac Arrest: Current Status and Future Directions
10 Gaps in out of Hospital SCD Protection? Most from ventricular tachyarrhythmias Outpatient defibrillation possibilities: -- Home AED -- EMS (Emergency Medical Services) -- ICD
11 Gaps in SCD Protection? Who doesn't receive SCD protection? Therapy delays Surgical contraindications (example: infection) Temporary SCA risk Heart transplant listing Terminal or potentially terminal condition Evaluation for SCA risk 90 or 40 day waiting periods (post revascularization / newly diagnosed) Waiting for therapeutic effects Changing risk factors High risk groups not yet studied for ICD effectiveness
12 Where does LifeVest Fit? Trying to impact a small period of time
13 The LifeVest Wearable Defibrillator Primary Functions: Detect ventricular fibrillation Detect ventricular tachycardia Deliver patient responsiveness test Defibrillate Secondary Functions: Arrhythmic event monitor Symptomatic event ECG recorder Heart Failure Management Tools (Remote Monitoring: LifeVest Network) Heart Rate / Pedometer / Body Angle While Sleeping / HF daily questionnaire
14 LifeVest
15
16
17
18
19 Dry, comfortable electrodes Defibrillation electrode ECG electrode Gel capsules
20 LifeVest Features Self gelling defibrillation electrodes No gel, no adhesive ECG electrodes Lightweight (1.8 lb monitor) Consciousness test before shock 150-joule biphasic shock Captures ECG 30 seconds before event Stores up to 75 minutes of ECG
21 Treatment Sequence
22 SS SS FB onset FB SS - 24 seconds between top and bottom - SS FB FB shock recovery
23 Example of Treatment Event
24
25
26 2017 AHA/ACC/HRS Guidelines WCD = LifeVest
27 2017 AHA/ACC/HRS Guidelines WCD = LifeVest
28 2017 AHA/ACC/HRS Guidelines
29 Insurance Coverage The LifeVest is covered by most health plans in the United States, including commercia, state and federal plans. This list summarizes the types of patient conditions and situations that are covered. The patient s specific health plan coverage policy should be reviewed to determine coverage for prescribing a LifeVest Primary prevention (EF<35% and MI, NICM or other DCM) including: after recent MI (coverage during the 40 day ICD waiting period) Before and after CABG or PTCA (Coverage during the 90 day ICD waiting period) Listed for cardiac transplant Recently diagnosed nonischemic cardiomyopathy (coverage during the 3 to 9 month ICD waiting period) NYHA class IV heart failure Terminal disease with life expectancy of less than 1 year ICD indications when patient condition delays or prohibits ICD implantation ICD explantation
30 LifeVest Experience First shock conversion success: 98%. Shocked event survival (conscious ER arrival or stayed at home): 94%. Most (77%) treated within 60 seconds (remaining delayed from response button use or VT programming)
31 WCD may be used for Bridge to ICD Outpatient, immediate, automatic, non-invasive protection against SCD, until ICD, or until no longer at risk Time For SCA Risk Assessment Outpatient, immediate, automatic, non-invasive protection against SCD, until ICD, or until no longer at risk Scheduling Tool Patient overflow Discharge Planning Tool Weekends Holidays
32 LifeVest Experience Experience with over 100,000 patients Average duration of use is 91 days Median daily use is 22.3% Survival After Deployment >94%
33 Case #1: First Month after MI Male patient, 62 years old Post MI with non-sustained VT EF was 15-20% Received LifeVest at discharge from hospital Treated for VT> 250 bpm by LifeVest during sleep: not once, but twice in the same night Patient originally insisted he was not shocked Two days later was treated again He has no recollection of any of the shocks
34 Case #2 Staged PCI Case Study Patient with STEMI underwent staged PCI with deployment of 2 drug-eluting stents Circumflex artery was staged 2 days later with successful deployment of a drug eluting stent Patient experienced episode of VF 5 days after D/C and was converted to NSR by a LifeVest shock Case illustrates importance of appropriately identifying physiological risk factors to protect to provide protection from SCA Patient had triple vessel disease and low EF = CADILLAC score 6 Additional co-morbidities Kooshkabadi Case Study
35 Case #3: Trapped in the Hospital Male patient, 37 years old, NICM Hospitalized until transplant because an implanted ICD was unable to terminate VF. He required simultaneous 300 joule shocks from two separate AEDs during the EP study. The LifeVest successfully terminated three induced episodes of VF with a single 150 joule shock. He was home for Christmas. As an outpatient, he was shocked successfully five times. After 14 months of waiting, he received a new heart.
36 Summary Constant monitoring and protection of SCD with superb results: 98% first shock conversion Designed for transitional SCD risk periods (the coverage gaps in ICD policy) Medicare and numerous insurances, including many Medicaid programs, cover wearable defibrillator use Allows time to determine long term course of treatment as well as ensuring patient returns for follow-up visit
37 Medical Orders Last 12 Months Cumulative
38 Questions? Thank you!
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationLifeVest. Sven Reek, Aarau. Conflict of interest: none
LifeVest Sven Reek, Aarau Conflict of interest: none WCD (LifeVest, ZOLL, Pittsburg,PA) Technical aspects Wearable garment with 4 dry ECG electrodes (detection) 3 defibrillation pads External defibrillator
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2017 Origination: 10/1988 Next Review: 12/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationRole of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death
Role of Non-Implantable Defibrillators in the Management of Patients at High Risk for Sudden Cardiac Death 29 October 2011 Update in Electrocardiography and Arrhythmias Zian H. Tseng, M.D., M.A.S. Associate
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2018 Origination: 10/1988 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationMEDICAL POLICY Cardioverter Defibrillators
POLICY........ PG-0224 EFFECTIVE......06/01/09 LAST REVIEW... 01/27/17 MEDICAL POLICY Cardioverter Defibrillators GUIDELINES This policy does not certify benefits or authorization of benefits, which is
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Wearable Cardioverter Defibrillators Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Wearable Cardioverter Defibrillators Implantable Cardioverter
More informationTitle: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationNational Medical Policy
National Medical Policy Subject: Policy Number: Cardiac Defibrillators - External, Automatic NMP269 Effective Date*: May 2006 Updated: May 2017 This National Medical Policy is subject to the terms in the
More informationWearable Cardioverter-Defibrillators
Medical Policy Manual Durable Medical Equipment, Policy No. 61 Wearable Cardioverter-Defibrillators Next Review: June 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER Medical Policies
More informationMedical Policy Manual. Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement
Medical Policy Manual Topic: Wearable Cardioverter-Defibrillators as a Bridge to Implantable Cardioverter-Defibrillator Placement Date of Origin: February 5, 2003 Section: Durable Medical Equipment Last
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationVest Prevention of Early Sudden Death Trial (VEST)
ACC Late Breaking Clinical Trials 2018 Vest Prevention of Early Sudden Death Trial (VEST) Jeffrey Olgin, MD, FACC Division of Cardiology, UCSF On behalf of the VEST Investigators Disclosures ClinicalTrials.gov
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationWearable Cardioverter-Defibrillators
Wearable Cardioverter-Defibrillators Policy Number: 2.02.15 Last Review: 12/2013 Origination: 10/1988 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationSudden Cardiac Death in Heart Failure: What do we need to know in 2018? Juan M. Aranda, Jr. MD FACC
Sudden Cardiac Death in Heart Failure: What do we need to know in 2018? Juan M. Aranda, Jr. MD FACC Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida Disclosures
More informationDOWNLOAD OR READ : VALIDITY OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES IN ASSESSING DAILY PHYSICAL ACTIVITY PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : VALIDITY OF CARDIAC IMPLANTABLE ELECTRONIC DEVICES IN ASSESSING DAILY PHYSICAL ACTIVITY PDF EBOOK EPUB MOBI Page 1 Page 2 validity of cardiac implantable electronic devices in assessing
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationSudden Cardiac Death
Sudden Cardiac Death management challenges of a global problem Zayd A. Eldadah, MD, PhD Co-Director, Cardiac Electrophysiology, Washington Hospital Center Director, Cardiac Electrophysiology, Georgetown
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationNEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS
NEIL CISPER TECHNICAL FIELD ENGINEER ICD/CRTD BASICS OBJECTIVES Discuss history of ICDs Review the indications for ICD and CRT therapy Describe basic lead and device technology Discuss different therapies
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationOut-Of-Hospital Management and Outcomes of Sudden Cardiac Death Abdelouahab BELLOU, MD, PhD
Out-Of-Hospital Management and Outcomes of Sudden Cardiac Death Abdelouahab BELLOU, MD, PhD Professor of Internal Medicine, Emergency Medicine, Therapeutics. Past President of the European Society for
More informationWhite Paper: Reducing Overutilization of Implantable
White Paper: Reducing Overutilization of Implantable Cardioverter-Defibrillators (ICDs) & the LifeVest For Hospital Groups, ASCs, and Specialty Medical Facilities Executive Summary Recent data suggest
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationSudden cardiac death (SCD) accounts for > deaths in
Sudden cardiac death (SCD) accounts for >300 000 deaths in the United States annually. 1 Although the majority of these deaths occur in low-risk populations 2 in which aggressive interventions are not
More informationPreventing cardiac arrest in high risk patients without indication for ICD
Preventing cardiac arrest in high risk patients without indication for ICD Martin C. Burke, DO Chief Scientific Officer CorVita Science Foundation COI DISCLOSURES Funded by and NIH/SBIR grant to AJ Medical
More information3/17/2014. NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death. Objectives
NCDR-14 ICD Registry WS # 24 Case Scenarios Including Syndromes w/ Risk of Sudden Death Denise Pond BSN, RN The following relationships exist related to this presentation: No Disclosures Objectives Discuss
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationWearable Cardioverter Defibrillators
Protocol Wearable Cardioverter Defibrillators Medical Benefit Effective Date: 08/01/17 Next Review Date: 05/19 Preauthorization Yes Review Dates: 05/07, 05/08, 05/09, 03/10, 01/11, 01/12, 01/13, 01/14,
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cardioverter-Defibrillators Page 1 of 32 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cardioverter-Defibrillators Professional Institutional Original Effective
More informationClinical Policy: Microvolt T-Wave Alternans Testing Reference Number: CP.MP.212
Clinical Policy: Reference Number: CP.MP.212 Effective Date: 03/05 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Wearable Cardioverter-Defibrillators in the Home Setting MP-001-MD-PA Medical Management Provider Notice Date: 11/15/2018;
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationWearable Devices for Heart Disease, Diabetes and Health
Wearable Devices for Heart Disease, Diabetes and Health Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health System
More informationIncidence of and Survival from Sudden Cardiac Arrest
Incidence of and Survival from Sudden Cardiac Arrest Vincent N Mosesso, Jr, MD Professor of Emergency Medicine University of Pittsburgh School of Medicine Disclosures Employer: University of Pittsburgh
More informationDEFIBRILLATORS. Prof. Yasser Mostafa Kadah
DEFIBRILLATORS Prof. Yasser Mostafa Kadah Basics Defibrillation is definitive treatment for life-threatening cardiac arrhythmias such as ventricular fibrillation Defibrillation consists of delivering therapeutic
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Cardioverter- ARBenefits Approval: 09/7/2011 Defibrillators Effective Date: 01/01/2012 Document: ARB0096 Revision Date: Code(s): C1721, C1722, C1777, C1882, C1895, C1896 and C1899
More informationSudden Cardiac Death and Asians Disclosures
Sudden Cardiac Death and Asians Disclosures 7 February 2009 Asian Heart and Vascular Symposium None Zian H. Tseng, M.D., M.A.S. Assistant Professor of Medicine Cardiac Electrophysiology Section University
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationAbbreviation List: 2017 by the American Heart Association, Inc. and the American College of Cardiology Foundation. 1
2017 AHA/ACC/HRS Systematic Review for the Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death Data Supplement Table of Contents Part 1. For Asymptomatic
More informationVest Prevention of Early Sudden Death Trial (VEST)
ACC Late Breaking Clinical Trials 2018 Vest Prevention of Early Sudden Death Trial (VEST) Jeffrey Olgin, MD, FACC Division of Cardiology, UCSF On behalf of the VEST Investigators Disclosures ClinicalTrials.gov
More informationSudden cardiac death (SCD) attributable to ventricular
Use of the Wearable Cardioverter Defibrillator in High-Risk Cardiac Patients Data From the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry) Valentina
More informationHanna K. Al-Makhamreh, M.D., FACC Interventional Cardiologist
Hanna K. Al-Makhamreh, M.D., FACC Interventional Cardiologist Introduction. Basic Life Support (BLS). Advanced Cardiac Life Support (ACLS). Cardiovascular diseases (CVDs) are the number one cause of death
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationM Series with Rectilinear Biphasic Waveform Defibrillator Option Indications for Use
DEFIBRILLATOR OPTION General Information Introduction M Series products are available with an advanced electrical design that provides a unique rectilinear biphasic waveform for defibrillation and cardioversion.
More informationSUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS
SUBCUTANEOUS IMPLANTABLE CARDIOVERTER DEFIBRILLATORS Protocol: CAR044 Effective Date: December 1, 2017 Table of Contents Page COMMERCIAL & MEDICAID COVERAGE RATIONALE... 1 MEDICARE COVERAGE RATIONALE...
More informationWearable Devices Emerging Strategies for Patient Management
Wearable Devices Emerging Strategies for Patient Management Pam R. Taub MD, FACC Director of Step Family Cardiac Wellness and Rehabilitation Center Associate Professor of Medicine UC San Diego Health System
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationOBJECTIVE. 1. Define defibrillation. 2. Describe Need and history of defibrillation. 3. Describe the principle and mechanism of defibrillation.
Defibrillators OBJECTIVE 1. Define defibrillation. 2. Describe Need and history of defibrillation. 3. Describe the principle and mechanism of defibrillation. 4. Types and classes of defibrillator 5. Describe
More informationImplantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in Disclosures
Implantable Cardioverter- Defibrillators (ICDs) for the Prevention of SCD: Appropriate Use in 2015 Andrew E. Epstein, MD Professor of Medicine, Cardiovascular Division University of Pennsylvania Chief,
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationDSED: Is It Real? Brent Myers, MD MPH FACEP CMO and EVP of Medical Operations, Evolution Health Associate CMO, American Medical Response
DSED: Is It Real? Brent Myers, MD MPH FACEP CMO and EVP of Medical Operations, Evolution Health Associate CMO, American Medical Response However beautiful the strategy, you should occasionally look at
More informationOut-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland
Out-of-hospital Cardiac Arrest Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland Conflict of Interest I have no conflict of interest to disclose regarding this presentation.
More informationExtended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death
Europace (2018) 00, 1 8 doi:10.1093/europace/euy091 CLINICAL RESEARCH Extended use of the wearable cardioverter-defibrillator in patients at risk for sudden cardiac death Valentina Kutyifa*, Katherine
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More informationNoninvasive Predictors of Sudden Cardiac Death
2011 년순환기관련학회춘계통합학술대회 Noninvasive Predictors of Sudden Cardiac Death 영남대학교의과대학순환기내과학교실신동구 Diseases associated with SCD Previous SCD event Prior episode of ventricular tachyarrhythmia Previous myocardial
More informationMADIT Studies: CRT in the Non-LBBB Patient and Other Findings. Arthur J. Moss, MD
MADIT Studies: CRT in the Non-LBBB Patient and Other Findings Arthur J. Moss, MD University of Rochester Medical Cntr. Rochester, NY 13 th Annual New Frontiers in Heart Failure Rx NYC, NY January 26, 2013
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More informationCardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides
Cardiac Devices CRT,ICD: Who is and is not a Candidate? Who Decides Colette Seifer MB(Hons) FRCP(UK) Associate Professor, University of Manitoba, Cardiologist, Cardiac Sciences Program, St Boniface Hospital
More informationNeed to Know: Implantable Devices. Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia
Need to Know: Implantable Devices Carolyn Brown RN, MN, CCRN Education Coordinator Emory Healthcare Atlanta, Georgia Disclosure Statement I have no relationships to disclose. Objectives Discuss the most
More informationQuality Measures MIPS CV Specific
Quality Measures MIPS CV Specific MEASURE NAME Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy CAHPS for MIPS Clinician/Group Survey Cardiac Rehabilitation Patient Referral from
More informationSPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM
SPORTS AND EXERCISE ADVICE IN PATIENTS WITH ICD AND PPM Rio De Janeiro 2016 Sport and Exercise Cardiology Symposium SBC/SOCERJ ACC Sharlene M. Day, MD Associate Professor, Cardiovascular Medicine Director,
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationCardiac Rehabilitation
Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health Plan Arizona, Inc.) Staywell of Florida
More informationPage 1 of 6. May 4,2012. ices, Inc. Independent External Review - AMENDED
May 4,2012 ices, Inc. RE: Independent External Review - AMENDED.. Covered Person: Health Carrier: VA External Review#: Date Assigned: Additional Files Received: 04/10/2012 05/02/2012 ISSUE TO BE ADDRESSED:
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD Introduction Cardiovascular disease is an important comorbidity for patients with chronic kidney disease (CKD). CKD patients are at high-risk for
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationDifferent indications for pacemaker implantation are the following:
Patient Resources: ICD/Pacemaker Overview ICD/Pacemaker Overview What is a pacemaker? A pacemaker is a device that uses low energy electrical pulses to prompt the heart to beat whenever a pause in the
More informationClinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation
J Arrhythmia Vol 25 No 1 2009 Original Article Clinical and Electrocardiographic Characteristics of Patients with Brugada Syndrome: Report of Five Cases of Documented Ventricular Fibrillation Seiji Takashio
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationKDIGO CAN WE PREVENT SUDDEN DEATH IN DIALYSIS PATIENTS? Charles A. Herzog, M.D., FACC, FAHA
CAN WE PREVENT SUDDEN DEATH IN DIALYSIS PATIENTS? Charles A. Herzog, M.D., FACC, FAHA Professor of Medicine, Hennepin County Medical Center/University of Minnesota Minneapolis, Minnesota USA Charles A.
More informationRegionalization of Post-Cardiac Arrest Care
Regionalization of Post-Cardiac Arrest Care David A. Pearson, MD, FACEP, FAAEM Department of Emergency Medicine Disclosures I have no financial interest, arrangement, or affiliations and no commercial
More informationRisk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD
Risk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD Professor of Medicine / Cardiology Professor of Obstetrics and Gynecology University of Southern California
More informationEarly Defibrillation. Dr. M. Ravishankar
Early Defibrillation Dr. M. Ravishankar THE CHAIN OF SURVIVAL CONCEPT Early Access Early CPR Early Defibrillation Early Advance Care 1 st Link 2 nd Link 3 rd Link 4 th Link Why early defibrillation VF
More informationPrior Authorization Review Panel MCO Policy Submission
Prior Authorization Review Panel MCO Policy Submission A separate copy of this form must accompany each policy submitted for review. Policies submitted without this form will not be considered for review.
More informationHospital and Physician Reimbursement Guide for ICD Implants
Hospital and Physician Reimbursement Guide for ICD Implants JULY 2014 CRDM Economics and Health Policy Hospital and Physician Reimbursement Guide for ICD Implants This guide has been developed to help
More informationTENNESSEE Project ADAM. Preventing Sudden Cardiac Death (SCD): Implementing your school s Public Access to Defibrillation (PAD) program.
TENNESSEE Project ADAM Preventing Sudden Cardiac Death (SCD): Implementing your school s Public Access to Defibrillation (PAD) program. In Tennessee IT S THE LAW. All schools equipped with an AED must
More informationSudden Cardiac Death in Korea : Epidemiology and Risk Factors
Sudden Cardiac Death in Korea : Epidemiology and Risk Factors Seok-Min Kang, MD, Ph D. Director, Heart Failure & Cardiac Wellness Center, Professor, Division of Cardiology, Severance Cardiovascular Hospital,
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationSubsequent management and therapies
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Subsequent management and therapies Marco Valgimigli, MD, PhD University of Ferrara ITALY
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationNon-Invasive Ablation of Ventricular Tachycardia
Non-Invasive Ablation of Ventricular Tachycardia Dr Shaemala Anpalakhan Newcastle upon Tyne Hospitals NHS Foundation Trust Freeman Road, Newcastle Upon Tyne, NE7 7DN Contact: shaemala@doctors.org.uk Introduction
More informationAssessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis
Assessment of Defibrillation Threshold upon Implantable Cardioverter-Defibrillator implant in Relation to patient s prognosis Investigator: Keiko Saito, MD Mentor: Yuji Saito, MD, PhD, FACP, FACC Department
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationSubcutaneous Implantable Cardioverter Defibrillator (ICD) System
Subcutaneous Implantable Cardioverter Defibrillator (ICD) System Policy Number: Original Effective Date: MM.06.025 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 3/24/201701/01/2019
More informationArthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY. DISCLOSURE INFORMATION Arthur J.
Saving Lives and Preventing Heart Failure: The MADIT Family of Trials Arthur J. Moss, MD Professor of Medicine/Cardiology University of Rochester Medical Center Rochester, NY Update in Electrocardiography
More informationIndex. cardiacep.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A AEDs. See Automated external defibrillators (AEDs) AF. See Atrial fibrillation (AF) Age as factor in SD in marathon runners, 45 Antiarrhythmic
More information